Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of TUL01101 in Adult Patients With Moderate to Severe Atopic Dermatitis
CTR20233576Phase 2Completed
- Sponsor
- The United Laboratories International Holdings
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TUL011018 in atopic dermatitis (AD), sponsored by The United Laboratories International Holdings. Started Nov 2023; status: completed.
02
Drugs
TUL011018
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20233576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233576.